Not yet recruiting
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis
2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source
Recruiting
Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis
NCT07809867· Phase 4· Istituto Giannina Gaslini· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Charite University, Berlin, Germany· Source
Recruiting
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
NCT06987539· Phase 2· Amgen· Source
Recruiting
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
NCT07470879· Phase 2· Pfizer· Source
Recruiting
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
NCT07554495· Phase 3· Alfasigma S.p.A.· Source
Recruiting
OLE Study With Filgotinib in JIA
NCT07553182· Phase 3· Alfasigma S.p.A.· Source
Recruiting
A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
2025-523079-44-00· Phase 3· Ascendis Pharma Endocrinology Division A/S· Source
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
NCT07227454· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma
2024-518167-35-01· Phase 2· Associazione Italiana Ematologia Oncologia Pediatrica· Source
Recruiting
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source
Recruiting
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
NCT07227857· Phase 1/2· Institut de Recherches Internationales Servier· Source
Contact: Renzo Guerrini, Pr
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850· Phase 2/3· argenx· Source
Recruiting
Open-label Study of ELA026 in Participants with sHLH (short title)
2025-520624-25-00· Phase 2/3· Electra Therapeutics Inc.· Source
Not yet recruiting
A Study to Learn About the Study Medicine Called Aztreonam-Avibactam in Neonates and Infants Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Bacteria
NCT06462235· Phase 2· Pfizer Inc.· Source
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medulloblastoma and other embryonal tumours
2024-518964-11-01· Phase 2· Azienda Ospedaliera Universitaria Meyer IRCCS· Source
Not yet recruiting
Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission
NCT06618937· Phase 4· Istituto Giannina Gaslini· Source
Recruiting
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939· Phase 3· Eli Lilly and Company· Source
Recruiting
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
NCT07334301· Phase 1/2· University of Birmingham· Source
Active, not recruiting
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· Phase 2/3· St. Anna Childrens Cancer Research Institute GmbH· Source
Active, not recruiting
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383· Phase 4· Novo Nordisk A/S· Source
Enrolling by invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source
Active, not recruiting
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
NCT06392009· Phase 1/2· GRIN Therapeutics, Inc.· Source
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744· Phase 3· AbbVie· Source
Active, not recruiting
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666· Phase 2/3· Cytokinetics· Source
Active, not recruiting
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Active, not recruiting
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06253221· Phase 3· Bristol-Myers Squibb· Source
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310· Phase 3· AstraZeneca· Source
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
NCT06111586· Phase 2· Sanofi· Source
Active, not recruiting
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907· Phase 3· AbbVie· Source
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630· Phase 3· AbbVie· Source
Active, not recruiting
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230· Phase 2· Boehringer Ingelheim· Source
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567· Phase 3· Takeda· Source
Active, not recruiting
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source
Recruiting
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
NCT05327894· Phase 3· Princess Maxima Center for Pediatric Oncology· Source
Active, not recruiting
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283· Phase 3· Bayer· Source
Active, not recruiting
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of anti TNF-alfa biosimilar molecules to the originators in children with active Juvenile Idiopathic Arthritis
2024-515557-22-00· Phase 4· Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico· Source
Enrolling by invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
NCT05374590· Phase 2/3· argenx· Source
Active, not recruiting
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325· Phase 3· Novo Nordisk A/S· Source
Showing 50 of 67.